Pseudomonas aeruginosa (CDC & FDA AR Isolate Bank #0266), IC Lung Infection Model, LD90-100

ITEM 608687

CONTACT FOR PRICING

STATUS Available

CONTACT CUSTOMER SERVICE

^{ADD TO FAVORITES}

^{ADD TO PANEL}

OVERVIEW

DOCUMENTS/REFERENCES

RELATED SERVICES

RELATED PRODUCTS

BIOLOGICAL INFORMATION

BACKGROUND INFORMATION

This model assesses the antimicrobial and protective efficacy of test articles in a lethal lung tissue infection with a carbapenem resistant P. aeruginosa clinical isolate. The model is conducted with immune-competent mice and may therefore be useful for evaluating immune modulatory agents, antibody therapeutics, and vaccines in addition to direct-acting small molecule antibacterial agents.

SPECIES

Pseudomonas aeruginosa

STRAIN COMMON NAME

AR-BANK#0266

ORGANISM

Gram-negative Bacteria

INCUBATION CONDITIONS

Aerobic

SOURCE

STRAIN SOURCE

CDC & FDA AR Isolate Bank

STRAIN SOURCE ID

AR Bank #0266

ASSAY INFORMATION

ASSAY TYPE

In Vivo

TESTING INFORMATION

PROCEDURE SUMMARY

Groups of 10 BALB/c derived female mice weighing 18 ± 2 g are used. Each animal is inoculated intranasally with a LD90-100 dose (2-4 x 10⁷ CFU/mouse) of Pseudomonas aeruginosa (AR-Bank#0266). Test substance and vehicle are administered one hour later by IP, PO, IV, or SC injection. Following test substance treatment as above, mortality is recorded daily during the following 10 days. Mortality data is graphed with the Kaplan Meier Method, and Significance is assessed with the Fisher's exact test. The mean survival time of vehicle and test article treatment groups are compared with ANOVA.

CRITERIA FOR SIGNIFICANCE

Mortality data is graphed with the Kaplan Meier Method and Significance is assessed with the Fisher's exact test.

TURNAROUND TIME

STANDARD

20 Days

CLINICAL RELEVANCE

THERAPEUTIC AREA

Infectious Disease

ADDITIONAL INFORMATION

BRAND

PDS

TESTING LOCATION

Taiwan - Taipei

OTHER INFORMATION

We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.